Filter by content type
Filter by year
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 10, 2022 - … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of this Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
August 15, 2022 - … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies phase 2 trials, partially offset by … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies phase 2 trials, partially …
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
May 16, 2022 - … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup expenses … clinical trial costs as a result of the completion of the CLASSICAL-Lung and SIGNAL studies, partially offset by setup …
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
March 31, 2022 - … of patients enrolled in clinical trials, especially the CLASSICAL-Lung and SIGNAL studies. General and Administrative Expenses. … . The Company believes that results of this Phase 1b/2 CLASSICAL-Lung trial supports increased benefit of …
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
March 9, 2022 - … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
January 4, 2022 - … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for … . Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate …
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 16, 2021 - … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
April 21, 2021 - … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer … Research … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell …
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 - … head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …